Ekso Bionics (EKSO) Earns Daily Coverage Optimism Score of 0.13
News coverage about Ekso Bionics (NASDAQ:EKSO) has trended somewhat positive on Monday, Accern reports. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ekso Bionics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.4319714451639 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Harwood Feffer LLP Announces Investigation of Ekso Bionics Holdings, Inc. – Business Wire (press release) (businesswire.com)
- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Active Mover – Nasdaq Journal (press release) (nasdaqjournal.com)
- EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ekso Bionics Holdings, Inc. – EKSO (markets.financialcontent.com)
A number of brokerages have recently commented on EKSO. ValuEngine upgraded Ekso Bionics from a “strong sell” rating to a “sell” rating in a report on Friday, November 17th. Zacks Investment Research lowered Ekso Bionics from a “hold” rating to a “sell” rating in a report on Monday, November 13th.
Shares of Ekso Bionics (NASDAQ EKSO) traded up $0.02 during midday trading on Monday, hitting $1.92. The company had a trading volume of 398,671 shares, compared to its average volume of 1,158,994. The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $113.82, a price-to-earnings ratio of -2.06 and a beta of 2.01. Ekso Bionics has a twelve month low of $0.99 and a twelve month high of $4.77.
Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Wednesday, November 8th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.40 million. Ekso Bionics had a negative net margin of 343.53% and a negative return on equity of 323.00%. equities analysts anticipate that Ekso Bionics will post -0.81 EPS for the current year.
In related news, insider Russ Angold sold 50,000 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $3.51, for a total value of $175,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.32% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with Analyst Ratings Network's FREE daily email newsletter.